Stamford, US Aug 22, 2025 (Issuewire.com) - Harrison Global Holdings Inc., formerly BloomZ Inc., has signed a strategic international partnership with Biotree Co., Ltd., a Korean biotech pioneer developing the worlds first natural product-based drug for metabolic syndrome.

Why This Matters to Investors

• Biotrees PH-100 has completed Phase 1 trials in the U.S. and Phase 2A trials in Korea, showing strong results in reducing inflammation and improving cardiovascular health.
• The drug is expected to receive conditional approval by mid-2026, opening up prescription-only revenue streams.
• Biotree is the first Korean firm to extract Seapolynol from Gamtae seaweedused in health foods, cosmetics, and pharmaceuticals.
• Harrison Global will help expand Biotrees reach into the U.S., Japan, China, and broader Asia through joint ventures, licensing, and localized development.

Strategic Synergy

This partnership blends Harrisons entertainment and youth engagement expertise with Biotrees biotech innovation, creating a hybrid growth engine across lifestyle, wellness, and media sectors.

Executive Insight

"Were thrilled to contribute to global health by supporting Biotrees breakthrough treatment," said Ryoshin Nakade, Co-CEO of Harrison Global. "This partnership reflects our commitment to innovation and international expansion."

Enrique Vargas

[email protected]

 More On Newslandnetwork ::

•   Find a Powerful Taste of Rap and Drill With Kvng Spugg's '2 Minute Drill'
•   Ernesto J. Gomez Publishes “Regrowth - How Organizations Can Overcome Stalling by Unlocking Their People´s Potential”
•   Robert Cowman, Recognized by BestAgents.us as a 2024 Top Agent
•   Cykelbutiker.nu Launches to Help Swedes Discover and Compare Local Bike Shops
•   21st China Int'l Agri Trade Fair concludes in Guangzhou with record number of buyers

(845) 288-0020